Stock Screener App

無料 -

インストール

3.65

4.29% 0.15

after-market

アフターアワーズ： 3.65

Fulcrum Therapeutics Inc (FULC)

概要ニュース株価時系列オプションチェーン Financials ディスカッション予測

Fulcrum Therapeutics Inc (FULC) 最新ニュース

BlackRock Portfolio Management LLC discloses 6.0% holding in THERAPEUTICS INC (FULC) - Stock Titan

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review

Form 4 Fulcrum Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa

Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation - NewMediaWire

Kevin Tang buys $891k of Fulcrum Therapeutics stock - Investing.com

Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder - Stock Titan

Fulcrum Therapeutics (FULC) holder adds 249,946 shares in open-market buys - Stock Titan

Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake - Stock Titan

Frontier tech research, news & data - MLQ.ai

Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN

Fulcrum Therapeutics (FULC) Slides 3.7% as Sellers Test Key Support Near $3.45Charm Flow - dars.gov.et

Fulcrum Therapeutics Inc. (FULC) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Market ReactionRevenue Surprise History - dars.gov.et

Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66 - Stock Titan

Fulcrum Therapeutics (FULC) director awarded 32,000 stock options - Stock Titan

Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan

Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike - Stock Titan

[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan

Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K. - Moomoo

After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN

Fulcrum Therapeutics | 8-K: Current report - Moomoo

Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus

Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Eastern Progress

Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000 Growth Benchmark - marketscreener.com

Price to earnings forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance

Fulcrum Therapeutics (FULC) Surges 5.26% as Biotech Momentum Builds, Testing Key ResistanceHigh Dividend Factor - dars.gov.et

[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan

Fulcrum Therapeutics, Inc. Actuals & Estimates (NASDAQ:FULC) - TradingView

EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan

EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan

Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks

Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan

Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey

Fulcrum Therapeutics (FULC) Advances 1.8% as Shares Test Resistance Near $4.12Growth ETF - dars.gov.et

Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey

Fulcrum plunges after discontinuing lead program - MSN

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securiti - The National Law Review

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire

2026-06-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | NDAQ:FULC | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire

Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations - NewMediaWire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewir - The National Law Review

Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Fulcrum Therapeutics Inc (FULC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

INSM

$108.32

0.80%

MRNA

$61.82

2.11%

ROIV

$34.51

1.71%

RPRX

$58.18

0.60%

ONC

$312.02

1.70%

ALNY

$267.47

5.54%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く